Beyond Sovaldi: PCSK9 Inhibitor Costs Are Also On PBMs’ Radar
The cost of the new class of drugs for hard-to-treat cholesterol could have an even bigger impact on the health care system than Sovaldi, executives from CVS Caremark and Express Scripts caution.
You may also be interested in...
The strong efficacy and sound safety data coming out of the Phase III programs presented at ACC have all eyes on the commercial opportunity for the PCSK9 inhibitor class. Ongoing outcomes trials and market impact of new cholesterol guidelines sparked discussion, and leading sponsors Amgen and Sanofi/Regeneron talked about the potential populations and differences in the devices and dosing of evolocumab and alirocumab.
Mark McClellan discusses whether CMS’s pending final version of the Medicare national coverage determination on Alzheimer’s drugs might change from the draft and whether the decision should be viewed as a precedent for drugs granted accelerated approvals.
Pharmacy organization urges the Centers for Medicare and Medicaid Services to recommend a dispensing fee commensurate with the effort involved in filling scripts for the drugs.